atb1651
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 8, 2021 (NCT05089409)
Timeline
Indications
Studied for
Mechanism of action
- Squalene monooxygenaseINHIBITOR
ERG1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06327295 | Phase 2 | Mar 30, 2024 | AmtixBio Co., Ltd. |
| NCT05089409 | Phase 1 | Nov 8, 2021 | AmtixBio Co., Ltd., Novotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AmtixBio Co., Ltd. | For profit | 2 | 2 | 2 | 2021 |
| Novotech | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1